ScholarIQanswers from OpenAlex & ORCID
Scott M. Wasserman
ResearcherPublications, citations & collaboration network
Scott M. Wasserman is a researcher indexed in ScholarIQ from OpenAlex & ORCID.
How many works does Scott M. Wasserman have?
ScholarIQindexed works
Scott M. Wasserman has 180 works in the ScholarIQ index. The count is the OpenAlex total, not the number of papers listed on this page.
How many citations does Scott M. Wasserman have?
ScholarIQcitation count
Scott M. Wasserman has 26,136 citations in the OpenAlex counts ScholarIQ stores.
What is the h-index of Scott M. Wasserman?
ScholarIQh-index
Scott M. Wasserman has an h-index of 62 in OpenAlex.
What is the i10-index of Scott M. Wasserman?
ScholarIQi10-index
Scott M. Wasserman has an i10-index of 99 in OpenAlex.
What is the ORCID of Scott M. Wasserman?
ScholarIQorcid
The ORCID for Scott M. Wasserman is on the source record.
What is the OpenAlex record for Scott M. Wasserman?
ScholarIQopenalex
The OpenAlex for Scott M. Wasserman is on the source record.
What are the most-cited papers on Scott M. Wasserman?
ScholarIQmost cited works
Evolocumab and Clinical Outcomes in Patients with Cardiovascular Disease
Marc S. Sabatine, Robert P. Giugliano, Anthony Keech, Narimon Honarpour, Stephen D. Wiviott, Sabina A. Murphy, Julia Kuder, Huei Wang, Thomas Liu, Scott M. Wasserman, Peter Sever, Terje R. Pedersen
Effect of Evolocumab or Ezetimibe Added to Moderate- or High-Intensity Statin Therapy on LDL-C Lowering in Patients With Hypercholesterolemia
Jennifer G. Robinson, Bettina S. Nedergaard, William J. Rogers, Jonathan Fialkow, Joel M. Neutel, David Ramstad, Ransi Somaratne, Jason C. Legg, Patric Nelson, Robert C. Scott, Scott M. Wasserman, Robert Weiss
Efficacy, safety, and tolerability of a monoclonal antibody to proprotein convertase subtilisin/kexin type 9 in combination with a statin in patients with hypercholesterolaemia (LAPLACE-TIMI 57): a randomised, placebo-controlled, dose-ranging, phase 2 study
Robert P. Giugliano, Nihar R. Desai, Payal Kohli, William J. Rogers, Ransi Somaratne, Fannie Huang, Thomas Liu, Satishkumar Mohanavelu, Elaine Hoffman, Shannon T McDonald, Timothy E Abrahamsen, Scott M. Wasserman, Robert C. Scott, Marc S. Sabatine
Efficacy, safety, and tolerability of a monoclonal antibody to proprotein convertase subtilisin/kexin type 9 as monotherapy in patients with hypercholesterolaemia (MENDEL): a randomised, double-blind, placebo-controlled, phase 2 study
Michael J. Koren, Robert C. Scott, Jae B. Kim, Beat Knüsel, Thomas Liu, Lei Lei, Michael A. Bolognese, Scott M. Wasserman
The effects of the cardiac myosin activator, omecamtiv mecarbil, on cardiac function in systolic heart failure: a double-blind, placebo-controlled, crossover, dose-ranging phase 2 trial
John G.F. Cleland, John R. Teerlink, Roxy Senior, Evgeny M. Nifontov, John Murray, Chim C. Lang, Vitaly A. Tsyrlin, Barry Greenberg, Jamil Mayet, Dárrel P. Francis, Tamaz Shaburishvili, Mark Monaghan, Mitchell Saltzberg, Ludwig Neyses, Scott M. Wasserman, Jacqueline H. Lee, Khalil G. Saikali, Cyril P. Clarke, Jonathan H. Goldman, Andrew A. Wolff, Fady I. Malik